Business Wire

Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

Share

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.

The latest results confirm that when SPL7013 is applied at the concentration of the SPL7013 COVID-19 nasal spray, it has potent virucidal activity, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19.

These data expand on the previously announced (see previous ASX announcement - 25 August 2020) data showing that SPL7013 has potent antiviral activity and inhibits infection of host cells by SARS‑CoV-2 when the compound is applied to the cells either before or after exposure to the virus. Earlier testing also showed that SPL7013 has a very favourable and high selectivity index1 (up to ~2200), indicating potent antiviral efficacy with minimal cellular toxicity. The high selectivity index of SPL7013 compares very favourably with the selectivity index against SARS-CoV-2 reported in the literature of 279 for remdesivir and 55 for hydroxychloroquine.2,3

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to be working with Professor Gallay to expedite the development of this important product. These latest data show that at clinically relevant concentrations (at the concentration of the SPL7013 COVID‑19 nasal spray), SPL7013 inactivates more than 99.9% of SARS-CoV-2, which represents a compelling feature for the product. This potent virucidal action is consistent with the activity seen for SPL7013 in other viruses, including HIV and HSV.”

Professor Gallay commented: “We have been working with Starpharma for a number of months now and are impressed with the antiviral data generated in our lab for SPL7013 against SARS-CoV-2. It is particularly exciting to see a product show such a potent and clear virucidal effect against this highly infectious virus, and for its antiviral activity to be present when SPL7013 is added either before or after exposure of cells to the virus.”

Dr Fairley added “Starpharma’s COVID-19 nasal spray has potential to be an important near-term preventative product, and given it is based on an already marketed active, its path to market is both faster and less complex than a completely new product. Another attractive feature of Starpharma’s SPL7013 COVID-19 nasal spray is that it is entirely complementary to other prevention measures such as PPE and vaccines. It also has special relevance where social distancing is not possible such as crowded environments and certain workplaces. The importance of having multiple preventative product strategies has been highlighted by the recent challenges with some vaccine trials. Starpharma’s topical antiviral nasal spray could play a role both prior to vaccines being available, and complementary to vaccines once available to further reduce risk.”

Starpharma is expediting the development of the SPL7013 nasal spray and has already completed reformulation, pilot product manufacture, selection of device and packaging components, identification of manufacturer and compiled regulatory documentation in preparation for submission (see previous ASX announcement - 25 August 2020). The company has also commenced commercial discussions across a range of distribution channels and customer groups (e.g. B2B, online platforms) and expects that the product will be ready for market in 1H CY2021.

SPL7013 Mechanism of antiviral action

SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. As for other viruses inhibited by SPL7013, SARS-CoV-2 infects human cells by using the characteristic viral surface proteins, or “spikes”, to attach to receptor proteins on the surface of human cells and SPL7013 blocks this interaction.

About SPL7013 COVID-19 nasal spray

SPL7013 is a broad-spectrum antiviral with potent SARS-CoV-2 activity and is also the active in VivaGel® marketed products approved in UK, Europe, Asia, Canada, Australia, and New Zealand. SPL7013 acts early in the viral replication cycle and has virucidal activity against SARS-CoV-2 with antiviral activity evident when used either before or after exposure of cells to the virus. SPL7013 inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins. SPL7013 has broad spectrum antiviral and virucidal effects, with activity demonstrated against a range of viruses, including HIV, herpes simplex virus (HSV), human papillomavirus (HPV), adenovirus, H1N1 influenza virus, hepatitis B virus (HBV) and Zika virus.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Disclosure
This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.


1 Selectivity index is a ratio of antiviral activity to cellular toxicity. The higher the selectivity index, the theoretically safer and more effective a compound would be in humans.

2 Pizzorno, A., et al., 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 104878. Advance online publication. https://doi.org/10.1016/j.antiviral.2020.104878

3 Liu, J., et al., 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 6(16). https://doi.org/10.1038/s41421-020-0156-0

Contact information

Media:
WE Communications
Rebecca Wilson
Mob: +61 417 382 391
rwilson@we-worldwide.com

Arthur Chan
+61 2 9237 2805
arthurc@we-worldwide.com

Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aviatrix Announces New Integrations to Expand Its Enterprise-Class Networking Solution on AWS3.12.2020 15:00:00 CETPress release

AWS re:Invent 2020 – Aviatrix, the cloud network platform, announced today that it will be showcasing at AWS re:Invent 2020 how enterprise customers are benefiting from its most recent achievement of AWS Outposts Ready designation and support for AWS Gateway Load Balancer (GWLB) as well as its multi-cloud transit capabilities for AWS Lambda serverless computing. Visit Aviatrix, an Amazon Web Services (AWS) Advanced Technology Partner that has achieved the AWS Networking Competency designation, at our AWS re:Invent 2020 virtual booth November 30 through December 18, to learn how Aviatrix’s leading cloud network platform delivers superior operational visibility, advanced networking and security control, and multi-cloud readiness for enterprises moving to AWS, or schedule a demo today. “Aviatrix provides the right business-critical cloud networking platform tools that enable us to do what we need to do for our hybrid environment. There’s so much flexibility; whether it’s network segmentat

Shape Therapeutics Unveils AAVid ™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy3.12.2020 14:00:00 CETPress release

Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign. The AAVidTM capsid discovery platform uses non-random mutational fitness to create massive capsid libraries of billions of unique AAV variants for direct-to-NHP in vivo biological selection. By combining cutting-edge DNA synthesis, advanced synthetic biology, next-generation sequence barcoding and machine learning algorithms, ShapeTX generates industry-leading library size and diversity to enable the development of best-in-class human therapeutics. “Wildtype first-generation AAVs are enabling the recent advances in gene therapy, but they have been plagued by toxicities in the clinic due in part to a lack of tissue specificity, resulting in the need for high doses. Our AAVidTM platform solves th

Dawex Data Exchange Platform Matches European Data Governance Act Criteria3.12.2020 14:00:00 CETPress release

Dawex, the leading data exchange technology company, today announced its Data Exchange technology matches with the requirements put forth by the European Data Governance Act. The European regulation acknowledges Data Exchange as an expert discipline requiring strict European-wide standards and criteria. The Act clarifies the role of data intermediaries, setting up a structure to foster trust in those intermediaries and the direction for data governance. The European Data Governance Acts lays down a notification procedure for providers of data sharing services to increase trust in the provision of these services throughout the European Union. The regulation specifies that the provider of data sharing services shall: Be neutral. Structurally separate its data intermediation services from any other value-added services it may provide Be established or have a legal representation within the European Union Be subjected to a general authorization to operate given by a member state Dawex Data

ExaGrid Wins “Enterprise Backup Hardware Vendor of the Year” and “Storage Performance Optimisation Company of the Year”3.12.2020 14:00:00 CETPress release

ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with “Enterprise Backup Hardware Vendor of the Year” and “Storage Performance Optimisation Company of the Year” at the annual Storage Awards, “The Storries,” announced virtually on November 26, 2020. Winners are determined by public vote, so receipt of these awards is especially meaningful as it reflects the voices of ExaGrid’s customers and partners, and further validates ExaGrid’s differentiated product architecture and outstanding customer support. This year’s win adds to ExaGrid’s previous wins at “The Storries” including winning “Enterprise Backup Hardware Product of the Year” in 2019, and “Enterprise Backup Storage Vendor of the Year” in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005089/en/ (Graphic: Business Wire) ExaGrid’s disk-cache Landing Zone for backup and restore performance is tiered to a

Mary Kay Inc. Expands Partnership With the Nature Conservancy to Protect Waterways Across the Globe3.12.2020 13:00:00 CETPress release

Last year,Mary Kay Inc., an international leader in corporate and social responsibility, announced the company had partnered with The Nature Conservancy to protect Texas fisheries and the Gulf of Mexico. Mary Kay is proud to announce they’ve expanded that partnership with The Nature Conservancy to impact waterways—and native species—the world over. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005076/en/ The Nature Conservancy, in partnership with Mary Kay, creates a water fund as Spain faces water scarcity and challenges with water quality. (Photo credit: © Ken Geiger) “All life on Earth began in and depends on our oceans,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Water is the most valuable resource on our planet, and it’s essential that we do our part to protect it. When we began scaling our partnership with The Nature Conservancy last year, we focused on the waterways surrounding our home state o

M7 Group Selects Hansen Customer Care and Billing to Spearhead Digital-Age Billing Operations3.12.2020 12:00:00 CETPress release

Hansen Technologies is pleased to announce a product upgrade and multi-year license and support agreement with Luxembourg-headquartered M7 Group for Hansen CCB, as the leading European pay-TV operator looks to consolidate billing operations and enhance the ability to meet the demands of a new, digital era. Hansen CCB is designed to enable service providers to capitalise on new business opportunities by quickly launching attractive products for specific target markets. The scalable customer-care and billing solution, designed for today’s leading pay-TV providers, delivers the power to bring new content and OTT partner services online fast. Hansen CCB is part of Hansen’s Create-Deliver-Engage Suite for communications service providers (CSPs). The upgrade programme will deliver a full consolidation of three billing platforms, supporting over three million subscribers across eight countries, onto one Hansen CCB platform, with phase one having already been successfully completed. Hans Troel